CAS Number108736-35-2
SynonymsB-naphthyl-D-ala-cys-tyr-D-trp*lys-val-cys-thr am; Somatuline; AUTOGEL; ANGIOPEPTIN; IPSTYL; DC-13-116; H-D-2-NAL-CYS-TYR-D-TRP-LYS-VAL-CYS-THR-NH2
Molecular FormulaC54H69N11O10S2
Molecular Weight1096.323
Purity98.00%
Density1.4±0.1 g/cm3
Boiling Point1508.2±65.0 °C at 760 mmHg
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 108736-35-2 |
| Catalog No. | 2A-9050418 |
| Chinese Name | 兰瑞肽 |
| Synonyms | B-naphthyl-D-ala-cys-tyr-D-trp*lys-val-cys-thr am; Somatuline; AUTOGEL; ANGIOPEPTIN; IPSTYL; DC-13-116; H-D-2-NAL-CYS-TYR-D-TRP-LYS-VAL-CYS-THR-NH2 |
| Molecular Formula | C54H69N11O10S2 |
| Molecular Weight | 1096.323 |
| Purity | 98.00 |
| Density | 1.4±0.1 g/cm3 |
| Boiling Point | 1508.2±65.0 °C at 760 mmHg |
| Storage Condition | -20°C, avoid light and dry |
| Application | Lanreotide (BIM 23014) is a somatostatin analog with anti-tumor activity. Lanreotide can be used in the study of carcinoid syndrome [1][2]. |
| SMILES | CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O |
| InChI Key | PUDHBTGHUJUUFI-HUZRFOFRSA-N |
| Hazard Symbols | transportation |
| MSDS | msds/50418_1_108736_35_2.pdf |
| Bioactivity | Lanreotide (BIM 23014) is a somatostatin analogue with antineoplastic activity. Lanreotide can be used for the research of carcinoid syndrome[1][2]. Related Catalog Research Areas >> Cancer Research Areas >> Endocrinology Signaling Pathways >> Others >> Others In Vitro Lanreotide (BIM 23014) (100 nM; 24-48 h) combines with radiation increasing in apoptotic sub-G1 proportion[1]. Lanreotide results in a dose-dependent decrease in GH3 cell colony forming units. Lanreotide at concentrations of 1, 10, 100, and 1000 nM results in cell survival rates of 75, 56, 39 and 27% respectively. The IC50 is 57 nM[1]. Lanreotide inhibits GH-secreting pituitary adenoma cell proliferation and hormone release in vitro[2]. In Vivo Lanreotide (2.5-10mg/kg; s.c.; daily for 5 days) results in tumor growth inhibition[1]. Animal Model: Male nude mice, 8 weeks old and 20-25 g in body weight (GH3 tumor-bearing nude mice)[1] Dosage: 2.5, 5, 10 mg/kg Administration: Subcutaneous; daily for 5 days Result: Produced tumor growth inhibition. References [1]. Ning S, et al. Lanreotide promotes apoptosis and is not radioprotective in GH3 cells.Endocr Relat Cancer. 2009 Sep;16(3):1045-55. [2]. Florio T, et al. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.Clin Endocrinol (Oxf). 2003 Jul;59(1):115-28. Chemical & Physical Properties Density 1.4±0.1 g/cm3 Boiling Point 1508.2±65.0 °C at 760 mmHg Molecular Formula C54H69N11O10S2 Molecular Weight 1096.323 Flash Point 865.9±34.3 °C Exact Mass 1095.467041 PSA 405.68000 LogP 2.89 Vapour Pressure 0.0±0.3 mmHg at 25°C Index of Refraction 1.689 InChIKey PUDHBTGHUJUUFI-HUZRFOFRSA-N SMILES CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O |
| Use of | Lanreotide (BIM 23014) is a somatostatin analogue with antineoplastic activity. Lanreotide can be used for the research of carcinoid syndrome[1][2]. Properties Name Lanreotide Synonym More Synonyms Lanreotide acetate salt Biological Activity Description Lanreotide (BIM 23014) is a somatostatin analogue with antineoplastic activity. Lanreotide can be used for the research of carcinoid syndrome[1][2]. Related Catalog Research Areas >> Cancer Research Areas >> Endocrinology Signaling Pathways >> Others >> Others References [2]. Florio T, et al. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.Clin Endocrinol (Oxf). 2003 Jul;59(1):115-28. Chemical & Physical Properties Molecular Formula C54H69N11O10S2 Exact Mass 1095.467041 PSA 405.68000 Index of Refraction 1.689 InChIKey PUDHBTGHUJUUFI-HUZRFOFRSA-N |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 Names specified by the United Nations (UN) European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Dangerous Regulations: No International Maritime Transport Dangerous Regulations Maritime Pollutants: No International Air Transport Risk Regulations: No 14.6 Special reminder to users No data available |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| tert-Butyl N-[3-(aminomethyl)benzyl]carbamate | 108467-99-8 | 2A-9050405 |
| Zinc acetylacetonate hydrate | 108503-47-5 | 2A-0201892 |
| 3-Amino-2-chlorobenzoic acid | 108679-71-6 | 2A-9050414 |
| 2-[(Aminoiminomethyl)thio]ethanesulfonic acid | 108710-70-9 | 2A-9050415 |
| 2-Amino-9,9-dimethylfluorene | 108714-73-4 | 2A-9050416 |
| 5,6,7,8-Tetrahydro-2H-cinnolin-3-one | 108749-03-7 | 2A-9050419 |
| 2,5-Dichloropentylamine | 108766-06-9 | 2A-9050421 |
| Magnesium ascorbyl phosphate | 108910-78-7 | 2A-9050424 |
| Fura 2-AM | 108964-32-5 | 2A-9050429 |
| 2-Heptyl-3-hydroxy-4(1H)-quinolinone | 108985-27-9 | 2A-9050431 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS